Oramed Pharmaceuticals (Seite 1565)
eröffnet am 28.03.07 10:26:47 von
neuester Beitrag 06.05.24 22:25:48 von
neuester Beitrag 06.05.24 22:25:48 von
Beiträge: 19.667
ID: 1.121.564
ID: 1.121.564
Aufrufe heute: 12
Gesamt: 1.542.273
Gesamt: 1.542.273
Aktive User: 0
ISIN: US68403P2039 · WKN: A1CTNU · Symbol: ORMP
2,4900
USD
+5,96 %
+0,1400 USD
Letzter Kurs 02:00:00 Nasdaq
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2000 | +471,16 | |
| 0,8700 | +134,44 | |
| 0,5700 | +55,23 | |
| 5,4500 | +41,56 | |
| 119,40 | +29,92 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8744 | -13,43 | |
| 4,1900 | -14,49 | |
| 1,4500 | -20,98 | |
| 11,200 | -43,26 | |
| 0,5215 | -87,06 |
Beitrag zu dieser Diskussion schreiben
Feedback
Moin moin
Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012
Jerusalem, Israel - Nov 7, 2011 - Oramed Pharmaceuticals Inc. (OTCBB: ORMP; www.oramed.com), a developer of oral delivery systems, announced today that results of a study performed using its oral insulin formulation, ORMD-0801, have been accepted for presentation at the 12th Annual Diabetes Technology Society Meeting. The abstract, titled "Concomitant oral and subcutaneous insulin therapy toward stabilization of uncontrolled T1DM," will be presented by Oramed's Chief Scientific Officer, Dr. Miriam Kidron, during the poster session being held from 4pm to 6:30pm (EST), on Thursday, November 8th. The meeting will take place at the Bethesda North Marriott Hotel & Conference Center.
Type 1 Diabetes Mellitus (T1DM), formerly known as juvenile diabetes, affects both young and adult populations. T1DM makes up approximately 5-10% of diabetes cases, and approximately $2 billion of the estimated $15 billion global insulin market. In this form of the disease, an autoimmune reaction destroys the body's insulin-producing cells in the pancreas making its patients completely dependent upon insulin from an external source.
T1DM is occasionally associated with instability and unpredictability of glycemic readings, resulting in poor control of blood sugar. In severe cases, this condition has a disruptive impact on patient quality of life, due to inadequate clinical solutions. The study to be presented at the Diabetes Technology Society Meeting, and conducted in 2010, evaluated the safety and stabilizing potential of concomitant oral and subcutaneous insulin therapy in volunteers diagnosed with unstable T1DM. Concomitant administration of Oramed's oral insulin formulation, ORMD-0801, and subcutaneous insulin proved safe and well tolerated. In addition, support with ORMD-0801 led to more frequent blood glucose readings within the healthy range (< 70 mg/dL) and to fewer readings within the high-risk zone (> 200 mg/dL).
The complete scientific abstract will be available on Oramed's website from the day of the meeting, here.
For additional information on the Diabetes Technology Society Meeting, please visit their website: http://diabetestechnology.org, or go directly to the conference agenda.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently approaching FDA-approved Phase 2 clinical trials, and with its GLP-1 analog capsule, currently approaching Phase 1b/2a trials. The company's corporate and R&D headquarters are based in Jerusalem.
The company's fact sheet can be viewed here.
For more information about the company, the content of which is not part of this press release, please visit www.oramed.com
Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward looking statements when we discuss the findings of the study to be presented at the Diabetes Technology Society Meeting and say that concomitant administration of oral and subcutaneous insulin proved safe and well tolerated. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching our clinical trials; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.
Company and Investor Relations Contact:
Oramed Pharmaceuticals
Aviva Sherman
USA: +1 646-240-4193
Int'l: + 972-54-792-4438
Email: aviva@oramed.com
Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012
Jerusalem, Israel - Nov 7, 2011 - Oramed Pharmaceuticals Inc. (OTCBB: ORMP; www.oramed.com), a developer of oral delivery systems, announced today that results of a study performed using its oral insulin formulation, ORMD-0801, have been accepted for presentation at the 12th Annual Diabetes Technology Society Meeting. The abstract, titled "Concomitant oral and subcutaneous insulin therapy toward stabilization of uncontrolled T1DM," will be presented by Oramed's Chief Scientific Officer, Dr. Miriam Kidron, during the poster session being held from 4pm to 6:30pm (EST), on Thursday, November 8th. The meeting will take place at the Bethesda North Marriott Hotel & Conference Center.
Type 1 Diabetes Mellitus (T1DM), formerly known as juvenile diabetes, affects both young and adult populations. T1DM makes up approximately 5-10% of diabetes cases, and approximately $2 billion of the estimated $15 billion global insulin market. In this form of the disease, an autoimmune reaction destroys the body's insulin-producing cells in the pancreas making its patients completely dependent upon insulin from an external source.
T1DM is occasionally associated with instability and unpredictability of glycemic readings, resulting in poor control of blood sugar. In severe cases, this condition has a disruptive impact on patient quality of life, due to inadequate clinical solutions. The study to be presented at the Diabetes Technology Society Meeting, and conducted in 2010, evaluated the safety and stabilizing potential of concomitant oral and subcutaneous insulin therapy in volunteers diagnosed with unstable T1DM. Concomitant administration of Oramed's oral insulin formulation, ORMD-0801, and subcutaneous insulin proved safe and well tolerated. In addition, support with ORMD-0801 led to more frequent blood glucose readings within the healthy range (< 70 mg/dL) and to fewer readings within the high-risk zone (> 200 mg/dL).
The complete scientific abstract will be available on Oramed's website from the day of the meeting, here.
For additional information on the Diabetes Technology Society Meeting, please visit their website: http://diabetestechnology.org, or go directly to the conference agenda.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently approaching FDA-approved Phase 2 clinical trials, and with its GLP-1 analog capsule, currently approaching Phase 1b/2a trials. The company's corporate and R&D headquarters are based in Jerusalem.
The company's fact sheet can be viewed here.
For more information about the company, the content of which is not part of this press release, please visit www.oramed.com
Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward looking statements when we discuss the findings of the study to be presented at the Diabetes Technology Society Meeting and say that concomitant administration of oral and subcutaneous insulin proved safe and well tolerated. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching our clinical trials; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.
Company and Investor Relations Contact:
Oramed Pharmaceuticals
Aviva Sherman
USA: +1 646-240-4193
Int'l: + 972-54-792-4438
Email: aviva@oramed.com
Antwort auf Beitrag Nr.: 43.777.271 von reaaalist am 01.11.12 23:12:11Salut reaaalist
Habe Heutenacht gegoogelt und keine News gefunden.
à propos:Ich werde jetzt die Zeit nutzen um mich mit Chartanalyse zu befassen.
Viel Zeit investieren, ich plane sogar über 3 St /tag
Deswegen könnte sein das mich etwas rar machen...
Aber keine Panik....werfe dann öfters 1 steriler Blick in Thread.
(als Pause zwischendurch poste ich
)
Ich will endlich 1 chartartist sein und 1 Guter...
Könnte vielleicht auch in Zükunft mit anderem Papiere handeln.
Habe sogar vor 1 Sofware-abonnement zu kaufen...nur wenn ich 1 gewisse Niveau erreicht haben.
Wir hören uns....
Posten dann nur weniger...
à bientôt
OC
Habe Heutenacht gegoogelt und keine News gefunden.
à propos:Ich werde jetzt die Zeit nutzen um mich mit Chartanalyse zu befassen.
Viel Zeit investieren, ich plane sogar über 3 St /tag
Deswegen könnte sein das mich etwas rar machen...
Aber keine Panik....werfe dann öfters 1 steriler Blick in Thread.
(als Pause zwischendurch poste ich
)Ich will endlich 1 chartartist sein und 1 Guter...
Könnte vielleicht auch in Zükunft mit anderem Papiere handeln.
Habe sogar vor 1 Sofware-abonnement zu kaufen...nur wenn ich 1 gewisse Niveau erreicht haben.
Wir hören uns....
Posten dann nur weniger...
à bientôt
OC
Antwort auf Beitrag Nr.: 43.777.167 von occitania am 01.11.12 22:29:40
ich werde meinen Avatar ändern
aber eigentlich passt es besser zu Dir!
PS. Kittel
Gruß r
ich werde meinen Avatar ändern
aber eigentlich passt es besser zu Dir!
PS. Kittel
Gruß r
Antwort auf Beitrag Nr.: 43.771.895 von reaaalist am 31.10.12 18:58:30Salut reaaalist
Bio steht dir gut
à bientôt
OC
Bio steht dir gut
à bientôt
OC
Antwort auf Beitrag Nr.: 43.767.318 von occitania am 30.10.12 17:14:01Moin Occi!
Glückwunsch du alter Börsenfuchs!
hast heute den Zehner geholt
nach News zu ORMP habe ich heute nicht gesucht!
Aber ich kann dir sagen, an der "Pille" wird fieberhaft gearbeitet
Gruß r
Glückwunsch du alter Börsenfuchs!
hast heute den Zehner geholt
nach News zu ORMP habe ich heute nicht gesucht!
Aber ich kann dir sagen, an der "Pille" wird fieberhaft gearbeitet
Gruß r
Trading Spotlight
Antwort auf Beitrag Nr.: 43.767.211 von reaaalist am 30.10.12 16:51:00Salut reaaalist
Kittel-Treffe nur alle 2 Woche.....bei mir
Meine Schäddel tut immer noch weh...
Und kömisches Geschmackt in Mund...immer noch...
Viel spass ..Heute.
à bientôt
OC
Oramed....behalte ich im Auge...
Kittel-Treffe nur alle 2 Woche...
..bei mirMeine Schäddel tut immer noch weh...
Und kömisches Geschmackt in Mund...immer noch...
Viel spass ..Heute.
à bientôt
OC
Oramed....behalte ich im Auge...
Antwort auf Beitrag Nr.: 43.767.133 von occitania am 30.10.12 16:35:31...Ich liebe solche Wörte...
ja, ich auch Occi,
noch schöner finde ich aber die Worte, wenn eine hübsche Frau zu mir sagt:
"Willst Du mit mir schlafen?"
Gruß r
PS. bin gleich weg zum "Kittel-Treffe mit Köter"
ja, ich auch Occi,
noch schöner finde ich aber die Worte, wenn eine hübsche Frau zu mir sagt:
"Willst Du mit mir schlafen?"
Gruß r
PS. bin gleich weg zum "Kittel-Treffe mit Köter"
Antwort auf Beitrag Nr.: 43.763.782 von reaaalist am 29.10.12 19:32:08Salut reaaalist,salut Wanduhr
Zitat:
This study and data from our previous studies, suggests that Oramed technologies the effective and well-tolerated delivery platform research and development risks and making significant clinical effect on diabetes management is. We will with confidence in direction IND approval in the U.S. Preceding
Naja....Effective...Ich liebe solche Wörte...
@reaaalist--->Faktenthread ?
à bientôt
OC
Zitat:
This study and data from our previous studies, suggests that Oramed technologies the effective and well-tolerated delivery platform research and development risks and making significant clinical effect on diabetes management is. We will with confidence in direction IND approval in the U.S. Preceding
Naja....Effective...Ich liebe solche Wörte...
@reaaalist--->Faktenthread ?
à bientôt
OC
Moin
mal was zum lesen
To spread hepatitis C primarily through blood contact propecia cost.
Posted By admin on October 28, 2012
To spread hepatitis C primarily through blood contact, including sterilized needles or medical equipment, injection or intranasal drug use or blood transfusions and medical procedures performed prior to 1992.3, 4 If you think on 16 Februaryhave exposed hepatitis C, get tested and ask treatment propecia cost .
‘The new Genesys HTA System to streamline the process set-up and offers my patients an effective way to address their menorrhagia,’said Christopher Guyer, a gynecologist at Queen Alexandra Hospital, Portsmouth.
ORMD-0801 has tolerated than a positive a positive safety profiles. No cumulative side – effects have been reported during this first study extended exposure to ORMD – 0,801th In addition was the %age of patient showing clinically relevant reductions in insulin, C – peptide is, fasting plasma glucose level and Hb1Ac still higher up in the ORMD-0801 cohort of, delivery platform compared to placebo. Moreover, mean decrease of insulin and CRP levels were found to be statistically significant for the 6-week once daily ORMD-0801 treatment. These results suggest in that ORMD-0801 dampen insulin overproduction of reprieving beta cells made their increased activity of. Reported results document the efficacy and safety of ORMD-0801 and demonstrate that oral insulin having a clinically relevant effect on to dose tested. That information collected to support the development to support the development of ORMD-0801 into the future registration trials. Harold Jacob, member Oramed Board of Directors of, said: The results of this trial once again the safety of oral of insulin installation Oramed These results indicate indicate a positive trend to efficacy of the tested orally insulin preparation. Executive Nadav Kedron, Chief by of Oramed Pharmaceuticals, added, This study and data from our previous studies, suggests that Oramed technologies the effective and well-tolerated delivery platform research and development risks and making significant clinical effect on diabetes management is. We will with confidence in direction IND approval in the U.S. Preceding. . (more…)
Quelle: http://www.kprm-prd.org/
Gruß r
PS. Meinungen
mal was zum lesen
To spread hepatitis C primarily through blood contact propecia cost.
Posted By admin on October 28, 2012
To spread hepatitis C primarily through blood contact, including sterilized needles or medical equipment, injection or intranasal drug use or blood transfusions and medical procedures performed prior to 1992.3, 4 If you think on 16 Februaryhave exposed hepatitis C, get tested and ask treatment propecia cost .
‘The new Genesys HTA System to streamline the process set-up and offers my patients an effective way to address their menorrhagia,’said Christopher Guyer, a gynecologist at Queen Alexandra Hospital, Portsmouth.
ORMD-0801 has tolerated than a positive a positive safety profiles. No cumulative side – effects have been reported during this first study extended exposure to ORMD – 0,801th In addition was the %age of patient showing clinically relevant reductions in insulin, C – peptide is, fasting plasma glucose level and Hb1Ac still higher up in the ORMD-0801 cohort of, delivery platform compared to placebo. Moreover, mean decrease of insulin and CRP levels were found to be statistically significant for the 6-week once daily ORMD-0801 treatment. These results suggest in that ORMD-0801 dampen insulin overproduction of reprieving beta cells made their increased activity of. Reported results document the efficacy and safety of ORMD-0801 and demonstrate that oral insulin having a clinically relevant effect on to dose tested. That information collected to support the development to support the development of ORMD-0801 into the future registration trials. Harold Jacob, member Oramed Board of Directors of, said: The results of this trial once again the safety of oral of insulin installation Oramed These results indicate indicate a positive trend to efficacy of the tested orally insulin preparation. Executive Nadav Kedron, Chief by of Oramed Pharmaceuticals, added, This study and data from our previous studies, suggests that Oramed technologies the effective and well-tolerated delivery platform research and development risks and making significant clinical effect on diabetes management is. We will with confidence in direction IND approval in the U.S. Preceding. . (more…)
Quelle: http://www.kprm-prd.org/
Gruß r
PS. Meinungen
Tach auch Leute, bin auch noch da. Traurig ist, dass das UNIVERSALZÄPCHEN noch nicht erfunden wurde und andere Substitute einen ungemein hohen Batterieverbrauch haben...schließlich haben wir Energiekrise, aber ich glaube, dass die ORAMEDWUNDERPILLE so richtig einschlagen wird......wenn sie denn dann auf den Markt kommt. (...nur nicht Dienstags auf unserem Wochenmarkt von 09:00-18:00 Uhr...da kommt kaum Jemand und kauft die Waren)
Gruß
Wanduhr
Gruß
Wanduhr
Durchsuchen
Oramed Pharmaceuticals
